Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — Investor Presentation (April 2023)
32 slides from Marinomed Biotech's investor presentation, Apr 11, 2023
Slide 1: Marinomed Biotech AG
Marinomed Biotech AG April 2023
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Company
Company Overview, Business Model, Equity Story © Marinomed Biotech AG 3
Slide 4: Marinomed at a glance
Marinomed at a glance Publicly listed biopharmaceutical company located in Korneuburg, Austria 2006 2008 2016 2019 2021 Foundation Launch of Invention of IPO and Marinosolv Marinosolv deal Carragelose Marinosolv clinical validation and Solv4U launch 13.5% Acropora Beteiligungs GmbH Business Segments
Slide 5: Equity Story
Equity Story Solid existing business, broad late-stage pipeline • Experienced management team • Solid revenue from marketed product portfolio and long-term growth perspective with maturing pipeline • Low clinical and regulatory risk: late-stage development and commercialization with partners lowers
Slide 6: Business model
Business model Marinomed Business Model Research & Pre-clinical Early clinical Supply chain organization for Innovation development development existing product portfolio MARINOMED High margin sales & licensing Generation of intellectual property CORE through partners Revenue through license deals R
Slide 7: Therapeutic Areas, Pipeline
Therapeutic Areas, Pipeline © Marinomed Biotech AG 7
Slide 8: Therapeutic Areas
Therapeutic Areas Proven track record with clinically validated and patent protected technologies VIROLOGY IMMUNOLOGY • Iota-carrageenan from red seaweed: • Marinosolv technology: solubilization for broad-spectrum virus blocker hydrophobic compounds • Clinically validated efficacy against Suspension
Slide 9: Carragelose
Carragelose Expertise in Virology – brought to market Mode of action Partner Logos (sample) Carragelose effect Protective layer Carragelose covers the viral surface unspecifically Product pictures (sample) Prophylactic and therapeutic efficacy clinically validated Baltics Broadly active across sever
Slide 10: Marinomed Strategy
Marinomed Strategy Building on solid existing business, entering new markets 2023+ 2023/24 2025+ • Maximize revenue • Expand in OTC • Expand in Rx • Geographical expansion • Geographical expansion • Progressing technology partnerships Tacrosolv Inflammatory eye diseases Future revenue Inhaleen Viral
Slide 11: Pipeline
Pipeline Late-stage projects with low risk and high upside potential © Marinomed Biotech AG 11
Slide 12: Marinomed Strategy
Marinomed Strategy Building on solid existing business, entering new markets 2023+ 2023/24 2025+ • Maximize revenue • Expand in OTC • Expand in Rx • Geographical expansion • Geographical expansion • Progressing technology partnerships Tacrosolv Inflammatory eye diseases Future revenue Inhaleen Viral
Slide 13: Tacrosolv (MAM-1003-1)
Tacrosolv (MAM-1003-1) Best-in-class macrolide immunosuppressant – fully solubilized with Marinosolv Solubilized Tacrolimus (Liquid formulation) Micelle-enabled solubilization Tacrolimus (FK506) Tacrosolv • Macrolide calcineurin inhibitor used for • Fully solubilized Tacrolimus immunosuppression, e.
Slide 14: Tacrosolv validated in clinical phase II trial
Tacrosolv validated in clinical phase II trial1 Anti-inflammatory activity in model indication allergic conjunctivitis shown1 Significant reduction of TOSS2 26% reduction of TOSS2 on day SIGNIFICANT REDUCTION4 on day 8 compared to placebo 14 8 within Tacrosolv study • of ocular symptoms on day 8 of
Slide 15: Attractive ophthalmic market
Attractive ophthalmic market Total target populations & market sizes Tacrosolv Allergic Herpetic stromal Vernal Dry eye disease conjunctivitis keratitis (HSK) keratoconjunctivitis US 49mn1 US 50mn4 US 18k7 US 33k7 EU5 59mn2 EU5 60mn5 EU5 18k7 EU5 162k7 US$ 6.5bn (2027)3 US$ 3.6bn (2028)6 US$ 300mn8
Slide 16: Marinomed Strategy
Marinomed Strategy Building on solid existing business, entering new markets 2023+ 2023/24 2025+ • Maximize revenue • Expand in OTC • Expand in Rx • Geographical expansion • Geographical expansion • Progressing technology partnerships Tacrosolv Inflammatory eye diseases Future revenue Inhaleen Viral
Slide 17: Solv4U technology partnerships
Solv4U technology partnerships Solution for drugs with low solubility • Solubilization services for external costumers • Based on patent protected and clinically validated Marinosolv technology • Suitable for a wide range of APIs (active pharmaceutical ingredients) PHASE I PHASE II PHASE III PHASE I
Slide 18: Solv4U technology partnerships
Solv4U technology partnerships Business Development • Launch in 2021 Examples of Marinosolv solubility enhancement in • Double-digit feasibility studies comparison to solubility in water successful • Customers won for phase II projects • Compounds from >10 substance classes solubilized • BD activiti
Slide 19: Financials
Financials Q3 2022, preliminary results FY2022 © Marinomed Biotech AG 19
Slide 20: Continuous double digit growth
Continuous double digit growth Strong Carragelose business and encouraging SOLV4U development Y-o-Y comparison of quarterly revenues (m€) Comments Key growth drivers 11.6 11.3 * • Adjusted for the Budesolv milestone in 2021 (€1.9m), revenues 5.9 rose from €9.7m to €11.3m (+16.5%); full year EBIT fig
Slide 21: Comfortable cash reach
Comfortable cash reach Low cash drain due to profitable revenues and inflows from convertible bond program • Ended December 2021 with €5.8m in cash • Raised +€7.4m in net cash through EIB (€6.0m), NÖBEG (€0.2m) and CNFP1 (€1.2m) • Received +€0.7m in milestones • Earned +€3.9m net cash through profit
Slide 22: Q3 Statement of profit or loss (IFRS)
Q3 Statement of profit or loss (IFRS) Higher revenues – improved EBIT €m 9M 2022 9M 2021 •1 Therein: 9M 2022 9M 2021 Revenues 1 7.1 5.7 Sale of goods 6.5 5.4 Other income 2 0.6 1.4 Cost of goods sold -4.5 -3.6 Materials expenses -4.6 -3.9 Margin 31.6% 33.6% Services expenses 3 -1.2 -3.3 •2 Primarily
Slide 23: Q3 Statement of financial position (IFRS)
Q3 Statement of financial position (IFRS) Assets €m Q3 2022 FY 2021 1 Inventories €m Q3 2022 FY 2021 Assets Goods for sale 0.3 0.1 Intangible assets 1.9 2.0 Unfinished goods 0.4 0.1 Property, plant and equipment 6.3 6.4 Raw materials 1.3 0.8 Deposits and other non-current Total inventories 2.0 1.0 0
Slide 24: Q3 Statement of financial position (IFRS)
Q3 Statement of financial position (IFRS) Equity and liabilities €m Q3 2022 FY 2021 •1 Capital increases through convertible note funding Equity and liabilities program Share capital 1.5 1.5 •2 Primarily related to EIB loan (€15.0m) and ERP/aws and Capital reserves 1 44.1 42.1 NÖBEG real estate refi
Slide 25: Outlook
Outlook © Marinomed Biotech AG 25
Slide 26: Project status updates (February 2023)
Project status updates (February 2023) Project Status/next steps Tacrosolv Enter into a partnership within the next 9-18 months Immunology Budesolv Work on registration with Luoxin for Greater China; additional partnership for Europe (6-12 months) Autoimmune gastritis Preclinical research; apply for
Slide 27: Financial calendar & IR contact
Financial calendar & IR contact Financial Calendar 2023 April 19, 2023 Publication of the Full Year Results 2022 May 23, 2023 Publication of the Results Q1 2023 Record Date for participation June 11, 2023 at the Annual General Meeting June 21, 2023 6th Annual General Meeting Stephanie Kniep August 1
Slide 28: www.marinomed.com
www.marinomed.com 0) Marinomed
Slide 29: Appendix
Appendix © Marinomed Biotech AG 29
Slide 30: Budesolv (MAM-1004-1)
Budesolv (MAM-1004-1) Nasal spray formulation of corticosteroid Budesonide for treating allergic rhinitis 7,6 • Marinosolv formulation: solution instead of suspension • Successful pivotal Phase III study 7,2 completed: • ~85% reduced dose • Significant faster onset of action 6,8 TNSS (<2h after trea
Slide 31: Carravin (MAM-2001-1)
Carravin (MAM-2001-1) Combination of Xylometazoline and Carrageenan • Active ingredient = Xylometazoline (decongestant) • Carrageenan supports Xylometazoline in reducing the duration and intensity of symptoms associated with viral infections of the respiratory tract • For the treatment of nasal cong
Slide 32: Sustainability
Sustainability Marinomed contributes to sustainability goals and adheres to ESG • Reduction of active ingredient by using Marinosolv solubilization technology • Sustainability of company premises (e.g., solar energy) • Promote environmentally friendly supply chains ENVIRONMENT • Therapies for people
Marinomed Biotech — Investor Presentation (April 2023) on 6ix